We are pleased to officially announce the launch of our new website, which reflects our expanding role as a leading professional service provider to pharmaceutical, biotechnology and medical device companies.
We are highlighting our services for Advanced Therapeutic Medicinal Products (ATMPs – which include cell and gene therapies). As our business continues to expand, the goal with this new website is to provide clear visibility on our services and the cross-functional experts we have at HiTech Health to support your company’s needs. The website now details the wide range of capabilities we offer surrounding cell and gene therapy services and at our process development laboratory in Galway, Ireland. This state-of-the-art facility is open for business and we can perform activities ranging from process and analytical development to personalised training in the lab.
Visitors can explore the many services we offer to a diverse range of clients ranging from early stage pre-clinical companies to large multinational corporations. Our focus is on Operations (CMC) from early product development through to product launch, HiTech Health has the experts that can enable a successful product registration and launch. Our team have led the development, manufacture, and supply of multiple products including cell and gene therapies to patients in several countries. We provide quality and compliance, QP and regulatory expertise, our team can be an extension of your internal resources. You can read about these services and much more on the new website. Going forward, we will continue to communicate regularly on the latest industry news and insights, as well as upcoming events where you can meet some of our team.
Recent News
Continuous Manufacturing: Industry reacts to new FDA guidelines
In February of this year the US Food and Drug Administration (FDA) released a 27-page draft guidance, ‘Quality Considerations for Continuous Manufacturing'. The FDA is seeking to encourage the adoption of continuous manufacturing as the agency believes it can improve...
Key Serialisation Considerations for Orphan Drugs
Adapting company strategies to serialisation Falsified medicines are counterfeit drugs that reach the market illegally. They have not been approved and may contain ingredients which are of poor quality and/or at the incorrect dose. Notably, falsified medicines pose...
What will Brexit mean for the pharmaceutical sector?
The UK life sciences industry contributes over £30bn to the UK economy, and supports almost half a million UK jobs. The UK is a leading centre of medical research and biopharmaceutical innovation, and is at the forefront of the drug development and approval process in...
Stay Up To Date
Connect with us to receive the latest HiTech Health and industry updates.